

The genetic basis of undiagnosed muscular dystrophies and myopathies

Results from 504 patients

Neurology® 2019;93:371. doi:10.1212/WNL.0000000000007477

In the article "The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients" by Savarese et al.,¹ the degree listed for the eleventh author, Dr. Alessandra Ruggieri, should be MSc rather than PhD. The authors regret the error.

Reference

1. Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. *Neurology* 2016;87:71–76.

Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy

Neurology® 2019;93:371. doi:10.1212/WNL.0000000000007478

In the article "Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy" by Munteanu et al.,¹ the degree listed for the third author, Dr. Alessandra Ruggieri, should be MSc rather than PhD. The authors regret the error.

Reference

1. Munteanu I, Ramachandran N, Ruggieri A, Awaya T, Nishino I, Minassian BA. Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy. *Neurology* 2015;84:1714–1716.

Congenital muscular dystrophies with defective glycosylation of dystroglycan

A population study

Neurology® 2019;93:371. doi:10.1212/WNL.0000000000007479

In the article "Congenital muscular dystrophies with defective glycosylation of dystroglycan: A population study" by Mercuri et al.,¹ the degree listed for the twenty-fifth author, Dr. Alessandra Ruggieri, should be MSc rather than PhD. The authors regret the error.

Reference

1. Mercuri E, Messina S, Bruno C, et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. *Neurology* 2009;72:1802–1809.

INTREPAD

A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

Neurology® 2019;93:371. doi:10.1212/WNL.0000000000007919

In the article "INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease" by Meyer et al.,¹ first published online April 5, 2019, Dr. Lafaille-Magnan's name should appear in the author list as Marie-Elyse Lafaille-Magnan. The authors regret the error.

Reference

1. Meyer PF, Tremblay-Mercier J, Leoutsakos J, et al. INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. *Neurology* 2019;92:e2070–e2080.

Neurology[®]

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

Neurology 2019;93;371

DOI 10.1212/WNL.0000000000007919

This information is current as of August 19, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/93/8/371.4.full
References	This article cites 1 articles, 1 of which you can access for free at: http://n.neurology.org/content/93/8/371.4.full#ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

